Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck
- Evaluate local control at 12 months in patients with recurrent squamous cell carcinoma
of the head and neck treated with cetuximab and stereotactic radiotherapy.
- Determine the incidence of cutaneous toxicity.
- Assess the care and development of skin reactions.
- Determine the quality of life of patients treated with this drug.
- Determine tumor response at 2 months.
OUTLINE: This is a multicenter study.
Patients receive cetuximab IV once weekly for 5 weeks. Patients undergo stereotactic
radiotherapy 3 times weekly during weeks 2 and 3.
After completion of study therapy, patients are followed at 2 months and then every 3 months
for 2 years.
Allocation: Non-Randomized, Primary Purpose: Treatment
Percentage of patients with nonprogressive disease at 12 months according to RECIST criteria
Eric Lartigau, MD, PhD
Centre Oscar Lambret
United States: Federal Government